Insight in eukaryotic ABC transporter function by mutation analysis

FEBS Letters

Volumn 580, Issue 4, 2006, Pages 1064-1084

  Frelet, Annie ^a   Klein, Markus ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Membrane protein; Polymorphisms; Processing; Site directed mutagenesis; Transport

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN YCF1; SULFONYLUREA RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; EUKARYOTIC CELL; HUMAN; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; SHORT SURVEY;

AMINO ACID SEQUENCE; ATP-BINDING CASSETTE TRANSPORTERS; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN TRANSPORT; SEQUENCE HOMOLOGY, AMINO ACID;

EUKARYOTA;

EID: 31844452412     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.01.024     Document Type: Short Survey

References (271)

1. M. Dean, A. Rzhetsky, and R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 11 2001 1156 1166
2. J.E. Walker, M. Saraste, M.J. Runswick, and N.J. Gay Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold EMBO J. 1 1982 945 951
3. S.C. Hyde, P. Emsley, M.J. Hartshorn, M.M. Mimmack, U. Gileadi, S.R. Pearce, M.P. Gallagher, D.R. Gill, R.E. Hubbard, and C.F. Higgins Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport Nature 346 1990 362 365
4. M. Azzaria, E. Schurr, and P. Gross Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance Mol. Cell. Biol. 9 1989 5289 5297
5. T.W. Loo, and D.M. Clarke Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities J. Biol. Chem. 270 1995 21449 21452
6. K. Szabo, E. Welker, E. Bakos, M. Muller, I. Roninson, A. Varadi, and B. Sarkadi Drug stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains J. Biol. Chem. 273 1998 10132 10138
7. I.L. Urbatsch, L. Beaudet, I. Carrier, and P. Gros Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotides at both sites Biochemistry 37 1998 4592 4602
8. I.L. Urbatsch, M. Julien, I. Carrier, M.E. Rousseau, R. Cayrol, P. Gros, and J.M. Ruysschaert Mutational analysis of conserved residues in the nucleotide binding sites of P-glycoprotein Biochemistry 39 2000 14138 14149
9. C.A. Hrycyna, M. Ramachandra, U.A. Germann, P.W. Cheng, I. Pastan, and M.M. Gottesman Both ATP sites of human P-glycoprotein are essential but not symmetric Biochemistry 38 1999 13887 13899
10. I.B. Holland, and M.A. Blight ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans J. Mol. Biol. 293 1999 381 399
11. A. Haimeur, G. Conseil, R.G. Deeley, and S.P.C. Cole The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation Curr. Drug Metab. 5 2004 21 53
12. G. Conseil, R.G. Deeley, and S.P.C. Cole Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas Biochem. Pharmacol. 69 2005 451 461
13. S.P.C. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
14. E.M. Leslie, R.G. Deeley, and S.P.C. Cole Multidrug resistance proteins in toxicology: Role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense Toxicol. Appl. Pharmacol. 204 2004 216 237
15. J. Konig, A.T. Nies, Y. Cui, and D. Keppler MRP2, the apical export pump for anionic conjugates I.B. Holland S.P.C. Cole K. Kuchler C.F. Higgins ABC Transporters: From Bacteria to Man 2003 Academic Press London 423 443
16. E. Bakos, R. Evers, J.A. Sinkule, A. Varadi, P. Borst, and B. Sarkadi Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions Mol. Pharmacol. 57 2000 760 768
17. S.M. Rowe, S. Miller, and E.J. Sorscher Cystic fibrosis N. Engl. J. Med. 352 2005 1992 2001
18. M.P. Anderson, R.J. Gregory, S. Thompson, D.W. Souza, S. Paul, R.C. Mulligan, A.E. Smith, and M.J. Welsh Demonstration that CFTR is a chloride channel by alteration of its anion selectivity Science 253 1991 202 205
19. D.C. Gadsby, and A.C. Nairn Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis Physiol. Rev. 79 1999 S77 S107
20. + channel regulators on CFTR chloride currents J. Gen. Physiol. 100 1992 573 591
21. - channel Physiol. Rev. 79 1999 S23 S45
22. + channels Biochim. Biophys. Acta 1461 1999 285 303
23. + channels Neuron 16 1996 1011 1017
24. H. Sakura, C. Ãmmãlã, P.A. Smith, F.M. Gribble, and F.M. Ashcroft Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic β-cells, brain, heart and skeletal muscle FEBS Lett. 377 1995 338 344
25. + channel J. Biol. Chem. 271 1996 24321 24324
26. + channel J. Physiol. 499 1997 715 720
27. F.M. Ashcroft Adenosine 5′-triphosphate-sensitive potassium channels Annu. Rev. Neurosci. 11 1988 97 118
28. + channels Trends Neurosci. 21 1998 288 294
29. L. Aguilar-Bryan, and J. Bryan Molecular biology of adenosine triphosphate-sensitive potassium channels Endocrinol. Rev. 20 1999 101 135
30. S. Seino ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies Annu. Rev. Physiol. 61 1999 337 362
31. + channel openers Pharmacol. Ther. 85 2000 39 53
32. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular and pharmalogical aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
33. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
34. G. Tombline, L.A. Bartholomew, I.L. Urbatsch, and A.E. Senior Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly J. Biol. Chem. 279 2004 31212 31220
35. G. Tombline, L.A. Bartholomew, K. Gimi, G.A. Tyndall, and A.E. Senior Synergy between conserved ABC signature Ser residues in P-glycoprotein catalysis J. Biol. Chem. 279 2004 5363 5373
36. G. Tombline, L.A. Bartholomew, G.A. Tyndall, K. Gimi, I.L. Urbatsch, and A.E. Senior Properties of P-glycoprotein with mutations in the "catalytic carboxylate" glutamate residues J. Biol. Chem. 279 2004 46518 46526
37. M.S. Szczypka, J.A. Wemmie, W.S. Moye-Rowley, and D.S. Thiele A yeast metal resistance protein similar to human cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein J. Biol. Chem. 269 1994 22853 22857
38. R. Tommasini, R. Evers, E. Vogt, C. Mornet, G.J. Zaman, A.H. Schinkel, P. Borst, and E. Martinoia The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1 Proc. Natl. Acad. Sci. USA 93 1996 6743 6748
39. J.M. Falcon-Perez, M.J. Mazon, J. Molano, and P. Eraso Functional domain analysis of the yeast ABC transporter Ycf1p by site-directed mutagenesis J. Biol. Chem. 274 1999 23584 23590
40. X.Q. Ren, T. Furukawa, Z.S. Chen, H. Okumura, S. Aoki, T. Sumizawa, A. Tani, M. Komatsu, X.D. Mei, and S. Akiyama Functional comparison between YCF1 and MRP1 expressed in Sf21 insect cells Biochem. Biophys. Res. Commun. 270 2000 608 615
41. G.E. Tusnady, E. Bakos, A. Varadi, and B. Sarkadi Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters FEBS Lett. 402 1997 1 3
42. G. Conseil, R.G. Deeley, and S.P.C. Cole Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters Pharmacogenet. Genomics 15 2005 523 533
43. K.P. Hopfner, A. Karcher, D.S. Shin, L. Craig, L.M. Arthur, J.P. Carney, and J.A. Tainer Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA-double strand break repair and the ABC-ATPase superfamily Cell 101 2000 789 800
44. V. Shyamala, V. Baichwal, E. Beall, and G.F. Ames Structure-function analysis of the histidine permease and comparison with cystic fibrosis mutations J. Biol. Chem. 266 1991 18714 18719
45. - channels with altered pore properties Nature 362 1993 160 164
46. S. McDonough, N. Davidson, H.A. Lester, and N.A. McCarty Novel pore-lining residues in CFTR that govern permeation and open channel block Neuron 13 1994 623 634
47. M. Cheung, and M.H. Akabas Identification of cystic fibrosis transmembrane conductance regulator channel-lining residues in and flanking the M6 membrane-spanning segment Biophys. J. 70 1996 2688 2695
48. P. Linsdell, J.A. Tabcharani, J.M. Rommens, Y.X. Hou, X.B. Chang, L.C. Tsui, J.R. Riordan, and J.W. Hanrahan Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions J. Gen. Physiol. 110 1997 355 364
49. P. Linsdell, J.A. Tabcharani, and J.W. Hanrahan Multi-ion mechanism for ion permeation and block in the cystic fibrosis transmembrane conductance regulator chloride channel J. Gen. Physiol. 110 1997 365 377
50. M.K. Mansoura, S.S. Smith, A.D. Choi, N.W. Richards, T.V. Strong, M.L. Drumm, F.S. Collins, and D.C. Dawson Cystic fibrosis transmembrane conductance regulator (CFTR) anion binding as a probe of the pore Biophys. J. 74 1998 1320 1332
51. C.J. Venglarik, B.D. Schultz, R.A. Frizzell, and R.J. Bridges ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism J. Gen. Physiol. 104 1994 123 146
52. K.L. Gunderson, and R.R. Kopito Conformational states of CFTR associated with channel gating: the role of ATP binding and hydrolysis Cell 82 1995 231 239
53. J.W. Hanrahan, M. Gentzsch, and J.R. Riordan The cystic fibrosis transmembrane conductance regulator (ABCC7) I.B. Holland S.P.C. Cole K. Kuchler C.F. Higgins ABC Proteins from Bacteria to Man 2003 Academic Press Amsterdam 589 618
54. X.B. Chang, J.A. Tabcharani, Y.X. Hou, T.J. Hensen, N. Kartner, N. Alon, J.W. Hanrahan, and J.R. Riordan Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites J. Biol. Chem. 268 1993 11304 11311
55. - conductance in mammalian heart J. Gen. Physiol. 101 1993 629 650
56. - channel by negative charge in the R domain J. Biol. Chem. 268 1993 20259 20267
57. D.J. Wilkinson, T.V. Strong, M.K. Mansoura, D.L. Wood, S.S. Smith, F.S. Collins, and D.C. Dawson CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain Am. J. Physiol. 273 1997 L127 L133
58. M.C. Winter, and M.J. Welsh Stimulation of CFTR activity by its phosphorylated R domain Nature 389 1997 294 296
59. B. Zerhusen, and J. Ma Function of the second nucleotide binding fold in the CFTR chloride channel FEBS Lett. 459 1999 177 185
60. L.S. Smit, D.J. Wilkinson, M.K. Mansoura, F.S. Collins, and D.C. Dawson Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator Proc. Natl. Acad. Sci. USA 90 1993 9963 9967
61. L. Aleksandrov, A. Aleksandrov, X.B. Chang, and J.R. Riordan The first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a rapid turnover J. Biol. Chem. 277 2002 15419 15425
62. M. Ramjeesingh, C. Li, E. Garami, L.J. Huan, K. Galley, Y. Wang, and C.E. Bear Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator) Biochemistry 38 1999 1463 1468
63. C. Randak, and M.J. Welsh An intrinsic adenylate kinase activity regulates gating of the ABC transporter CFTR Cell 115 2003 837 850
64. - channels J. Gen. Physiol. 121 2003 17 36
65. A.L. Berger, M. Ikuma, and M.J. Welsh Normal gating of CFTR requires ATP binding to both nucleotide binding domains and hydrolysis at the second nucleotide binding domain Proc. Natl. Acad. Sci. USA 102 2005 455 460
66. C. Basso, P. Vergani, A.C. Nairn, and D.C. Gadsby NBD1 might remain nucleotide-bound throughout CFTR channel gating cycle Biophys. J. 82 2002 12a
67. S. Zeltwanger, F. Wang, G.T. Wang, K.D. Gillis, and T.C. Hwang Gating of cysticfibrosis transmembrane conductance regulator chloride channels by adenosine triphosphate hydrolysis. Quantitative analysis of a cyclic gating scheme J. Gen. Physiol. 113 1999 541 554
68. M.R. Carson, and M.J. Welsh Structural and functional similarities between the nucleotide-binding domains of CFTR and GFP-binding proteins Biophysics 69 1995 2443 2448
69. A.C.J. Powe, L. Al-Nakkash, M. Li, and T.C. Hwang Mutation of Walker-A lysine 464 in cystic fibrosis transmembrane conductance regulator reveals functional interaction between its nucleotide-binding domains J. Physiol. 539 2002 333 346
70. J.F. Cotten, and M.J. Welsh Covalent modification of the nucleotide binding domains of cystic fibrosis transmembrane conductance regulator J. Biol. Chem. 273 1998 31873 31879
71. - channel activity Am. J. Physiol. 274 1998 L305 L312
72. E. Schneider, and S. Hunke ATP-binding cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains FEMS Microbiol. Rev. 22 1998 1 20
73. 2+-independent ATP binding of the sulfonylurea receptor SUR1 J. Biol. Chem. 272 1997 22983 22986
74. ATP channel activation by Mg-ADP and diazoxide EMBO J. 16 1997 1145 1152
75. ATP channel activity by diazoxide and MgADP Distinct functions of the two nucleotide binding folds of the sulfonylurea receptor J. Gen. Physiol. 110 1997 643 654
76. N. D'hahan, C. Moreau, A.L. Prost, H. Jacquet, A.E. Alekseev, A. Terzic, and M. Vivaudou Pharmalogical plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP Proc. Natl. Acad. Sci. USA 96 1999 12162 12167
77. + channel openers J. Biol. Chem. 275 2000 717 720
78. M. Matsuo, N. Kioka, T. Amachi, and K. Ueda ATP binding properties of the nucleotide-bindings folds of SUR1 J. Biol. Chem. 274 1999 37479 37482
79. M. Matsuo, K. Tanabe, N. Kioka, T. Amachi, and K. Ueda Different binding properties and affinities for ATP and ADP among sulfonylurea receptor subtypes, SUR1, SUR2A and SUR2B J. Biol. Chem. 275 2000 28757 28763
80. K. Ueda, J. Komine, M. Matsuo, S. Seino, and T. Amachi Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide Proc. Natl. Acad. Sci. USA 96 1999 1268 1272
81. T. Matsuoka, K. Matsushita, Y. Katayama, A. Fujita, K. Inageda, M. Tanemoto, A. Inanobe, S. Yamashita, Y. Matsuzawa, and Y. Kurachi C-terminal tails of sulfonylurea receptors control ADP-induced activation Circ. Res. 87 2000 873 880
82. ATP channel complex FASEB J. 14 2000 1943 1952
83. + conductance Neuron 31 2001 233 245
84. + channels J. Biol. Chem. 277 2002 14206 14210
85. M. Schwanstecher, C. Sieverding, H. Dörschner, I. Gross, L. Aguilar-Bryan, C. Schwanstecher, and J. Bryan Potassium channel openers require ATP to bind to and act through sulfonylurea receptors EMBO J. 17 1998 5529 5535
86. ATP channels Circ. Res. 90 2000 554 561
87. ATP channels Biochem. J. 379 2004 173 181
88. S.N. Magge, S.L. Shyng, C. MacMullen, L. Steinkrauss, A. Ganguly, L.E.L. Katz, and C.A Stanley Familial leucine-sensitive hypoglycemia of infancy due to a dominant mutation of the β-cell sulfonylurea receptor J. Clin. Endocrinol. Metab. 89 2004 4450 4456
89. ATP channels FEBS Lett. 482 2000 59 64
90. X.Q. Ren, T. Furukawa, M. Haraguchi, T. Sumizawa, S. Aoki, M. Kobayashi, and S. Akiyama Function of the ABC signature sequences in the human multidrug resistance protein 1 Mol. Pharmacol. 65 2004 1536 1542
91. Y.X. Hou, L. Cui, J.R. Riordan, and X.B. Chang Allosteric interactions between the two non-equivalent nucleotide binding domains of multidrug resistance protein MRP1 J. Biol. Chem. 275 2000 20280 20287
92. 4 transport J. Biol. Chem. 278 2003 30764 30771
93. M. Muller, E. Bakos, E. Welker, A. Varadi, U.A. Germann, M.M. Gottesman, B.S. Morse, I.B. Roninson, and B. Sarkadi Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein J. Biol. Chem. 271 1996 1877 1883
94. I.L. Urbatsch, K. Gimi, S. Wilke-Mounts, N. Lerner-Marmarosh, M.E. Rousseau, P. Gros, and A.E. Senior Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein J. Biol. Chem. 276 2001 26980 26987
95. I.L. Urbatsch, K. Gimi, S. Wilke-Mounts, and A.E. Senior Conserved Walker A Ser residues in the catalytic sites of P-glycoprotein are critical for catalysis and involved primarily at the transition state step J. Biol. Chem. 275 2000 25031 25038
96. D.J. Wilkinson, M.K. Mansoura, P.Y. Watson, L.S. Smit, F.S. Collins, and D.C. Dawson CFTR: the nucleotide binding folds regulate the accessibility and stability of the activated state J. Gen. Physiol. 107 1996 103 119
97. J.E. Moody, L. Millen, D. Binns, J.F. Hunt, and P.J. Thomas Cooperative ATP-dependent association of the nucleotide binding cassettes during the catalytic cycle of ATP-binding cassette transporters J. Biol. Chem. 277 2002 21111 21114
98. J.D. Campbell, M.S. Sansom, and F.M. Ashcroft Potassium channel regulation EMBO J. 4 2003 1038 1042
99. + channel Mol. Pharmacol. 65 2004 1198 1207
100. Y.X. Hou, L. Cui, J.R. Riordan, and X.B. Chang ATP binding to the first nucleotide binding domain of multidrug resistance protein MRP1 increases binding and hydrolysis of ATP and trapping of ADP at the second domain J. Biol. Chem. 277 2002 5110 5119
101. L. Cui, Y.X. Hou, J.R. Riordan, and X.B. Chang Mutations of the Walker B motif in the first nucleotide binding domain of multidrug resistance protein MRP1 prevent conformational maturation Arch. Biochem. Biophys. 392 2001 153 161
102. I.L. Urbatsch, B. Sankaran, S. Bhagat, and A.E. Senior Both P-glycoprotein nucleotide-binding sites are catalytically active J. Biol. Chem. 270 1995 26956 26961
103. M. Julien, and P. Gros Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity Biochemistry 39 2000 4559 4568
104. I. Carrier, M. Julien, and P. Gross Analysis of catalytic carboxylate mutants E552Q and E1197Q suggests asymmetric ATP hydrolysis by the two nucleotide binding domains of P-glycoprotein Biochemistry 42 2003 12875 12885
105. Z.E. Sauna, M. Müller, X.H. Peng, and S.V. Ambukdar Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1) Biochemistry 41 2002 13989 14000
106. J.M. Falcon-Perez, M. Martinez-Burgos, J. Molano, M.J. Mazon, and P. Eraso Domain interactions in the yeast ATP binding cassette transporter Ycf1p: intragenic suppressor analysis by mutations in the nucleotide binding domains J. Bacteriol. 183 2001 4761 4770
107. R.J. Gregory, D.P. Rich, S.H. Cheng, D.W. Souza, S. Paul, P. Manavalan, M.P. Anderson, M.J. Welsh, and A.E. Smith Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide binding domains 1 and 2 Mol. Cell. Biol. 11 1991 3886 3893
108. C. Proff, and R. Kölling Functional asymmetry of the two nucleotide binding domains in the ABC transporter Ste6 Mol. Gen. Genet. 264 2001 883 893
109. T.W. Loo, M.C. Bartlett, and D.M. Clarke The "LSGGQ" motif in each nucleotide binding domain of human P-glycoprotein is adjacent to the opposite walker A sequence J. Biol. Chem. 277 2002 41303 41306
110. Y. Yang, D.C. Devor, J.F. Engelhardt, S.A. Ernst, T.V. Strong, F.S. Collins, J.A. Cohn, R.A. Frizell, and J.M. Wilson Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR Hum. Mol. Genet. 2 1993 1253 1261
111. J. Logan, D. Hiestand, P. Daram, Z. Huang, D.D. Muccio, J. Hartmann, B. Haley, W.J. Cook, and E.J. Sorscher Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding J. Clin. Invest. 94 1994 228 236
112. P. Melin, V. Thoreau, C. Norez, F. Bilan, A. Kitzis, and F. Becq The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of chloride channels by genistein Biochem. Pharmacol. 67 2004 2187 2196
113. B. Illek, L. Zhang, N.C. Lewis, R.B. Moss, J.Y. Dong, and H. Fischer Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein Am. J. Physiol. 277 1999 C833 C839
114. M. Matsuo, M. Dabrowski, K. Ueda, and F.M. Ashcroft Mutations in the linker domain of NBD2 of SUR inhibits transduction but not nucleotide binding EMBO J. 21 2002 4250 4258
115. Z. Szentpetery, A. Kern, K. Liliom, B. Sarkadi, A. Varadi, and E. Bakos The role of the conserved glycines of ATP-binding cassette signature motifs of MRP1 in the communication between the substrate-binding site and the catalytic centers J. Biol. Chem. 279 2004 41670 41678
116. Z. Szentpetery, B. Sarkadi, E. Bakos, and A. Varadi Functional studies on the MRP1 multidrug transporter: characterization of ABC-signature mutant variants Anticancer Res. 24 2004 449 455
117. P. Gros, L. Beaudet, and I.L. Urbatsch Yeast as en expression system for the study of P-glycoprotein and other ABC transporters Acta Physiol. Scand. 163 1998 S219 S225
118. A.B. Shapiro, and V. Ling The mechanism of ATP-dependent multidrug transport in P-glycoprotein Acta. Physiol. Scand. 163 1998 S227 S234
119. E. Bakos, I. Klein, E. Welker, K. Szabo, M. Müller, B. Sarkadi, and A. Varadi Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature regions Biochem. J. 323 1997 777 783
120. S.H. Cheng, R.J. Gregory, J. Marshall, S. Paul, D.W. Souza, G.A. White, C.R. Riordan, and A.E. Smith Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis Cell 63 1990 827 834
121. F. Buyse, M. Vandenbranden, and J.M. Ruysschaert Mistargeted MRPdelta F728 mutant is rescued by intracellular GSH FEBS Lett. 578 2004 145 151
122. M. Sharma, F. Pampinella, C. Nemes, M. Benharouga, J. So, K. Du, K.G. Bache, B. Papsin, N. Zerangue, H. Stenmark, and G.L. Lukacs Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes J. Cell Biol. 164 2004 923 933
123. M. Sharma, M. Benharouga, W. Hu, and G.L. Lukacs Conformational and temperature-sensitive stability defects of the ΔF508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments J. Biol. Chem. 276 2001 8942 8950
124. K. Du, M. Sharma, and G.L. Lukacs The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-transcriptional folding of CFTR Nat. Struct. Mol. Biol. 26 2005 17 25
125. J.R. Riordan Assembly of functional CFTR chloride channels Annu. Rev. Physiol. 67 2005 701 718
126. T.C. Hwang, F. Wang, C.H. Yang, and W.W. Reenstra Genistein potentiates wild-type and delta F508-CFTR channel activity Am. J. Physiol. 273 1997 C988 C998
127. T.W. Loo, M.C. Bartlett, and D.M. Clarke Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound Mol. Pharm. 2 2005 407 413
128. M. Gelman, and R. Kopito Rescuing protein conformation: prospects for pharmacological therapy of cystic fibrosis J. Clin. Invest. 110 2002 1591 1597
129. M. Gentzsch, X.B. Chang, L. Cui, Y. Wu, V.V. Ozols, A. Choudhury, R.E. Pagano, and J.R. Riordan Endocytic trafficking routes of wild type and ΔF508 cystic fibrosis transmembrane conductance regulator Mol. Biol. Cell 15 2004 2684 2696
130. M. Massiah, Y. Ko, P. Pedersen, and A. Mildvan Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing ΔF508 mutation Biochemistry 38 1999 7453 7461
131. F. Wang, S. Zeltwanger, S. Hu, and T.C. Hwang Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels J. Physiol. 524 2000 637 648
132. I. Tsigelny, M. Hotchko, J.X. Yuan, and S.H. Keller Identification of molecular determinants that modulate trafficking of DeltaF508 CFTR, the mutant ABC transporter associated with cystic fibrosis Cell Biochem. Biophys. 42 2005 41 53
133. ATP channels caused by a sulfonylurea receptor 1 mutation associated with persisten thyperinsulinemic hypoglycemia of infancy Proc. Natl. Acad. Sci. USA 98 2001 2882 2887
134. T. Hoof, A. Demmer, M.R. Hadam, J.R. Riordan, and B. Tummler Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1 J. Biol. Chem. 269 1994 20575 20583
135. T.W. Loo, and D.M. Clarke Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators J. Biol. Chem. 272 1997 709 712
136. D.J. Katzmann, E.A. Epping, and W.S. Moye-Rowley Mutational disruption of plasma membrane trafficking of Saccharomyces cerevisiae Yor1p, a homologue of mammalian multidrug resistance protein Mol. Cell. Biol. 19 1999 2998 3009
137. L.S. Smit, T.V. Strong, D.J. Wilkinson, M. Macek Jr., M.K. Mansoura, D.L. Wood, J.L. Cole, G.R. Cutting, J.A. Cohn, and D.C. Dawson Missense mutations (G480C) in the CFTR gene associated with protein mislocalization but normal chloride channel activity Hum. Mol. Genet. 4 1995 269 273
138. A.L. Berger, M. Ikuma, J.F. Hunt, P.J. Thomas, and M.J. Welsh Mutations that change the position of the putative γ-phosphate linker in the nucleotide binding domains of CFTR alter channel gating J. Biol. Chem. 277 2002 2125 2131
139. D.N. Sheppard, L.S. Ostedgaard, M.C. Winter, and M.J. Welsh Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency EMBO J. 14 1995 876 883
140. M.A. Harrington, and R.R. Kopito Cysteine residues in the nucleotide binding domains regulate the conductance state of CFTR channels Biophys. J. 82 2002 1278 1292
141. J.F. Pollet, J. van Geffel, E. van Stevens, R. van Geffel, R. Beauwens, A. Bollen, and P. Jacobs Expression and intracellular processing of chimeric and mutant CFTR molecules Biochim. Biophys. Acta 1500 2000 59 69
142. F. Mendes, M.R. Rosa, A. Dragomir, C.M. Farinha, G.M. Roomans, M.D. Amaral, and D. Penque Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed protein Biochem. Biophys. Res. Commun. 311 2003 665 671
143. D.P. Rich, R.J. Gregory, S.H. Cheng, A.E. Smith, and M.J. Welsh Effect of deletion mutations on the function of CFTR chloride channels Receptors Channels 1 1993 221 232
144. J.D. Campbell, P. Proks, J.D. Lippiat, M.S. Sansom, and F.M. Ashcroft Identification of a functionally important negatively charged residue within the second catalytic site of the SUR1 nucleotide binding domains Diabetes 53 2004 S123 S127
145. + channels: implication for dimerization of nucleotide-binding domains to induce channel opening Mol. Pharmacol. 66 2004 807 816
146. Q. Zhao, and X.B. Chang Mutation of the aromatic amino acid interacting with adenine moiety of ATP to a polar residue alters the properties of multidrug resistance protein 1 J. Biol. Chem. 279 2004 48505 48512
147. K. Hashimoto, T. Uchiumi, T. Konno, T. Ebihara, T. Nakamura, M. Wada, S. Sakisaka, F. Maniwa, T. Amachi, K. Ueda, and M. Kuwano Trafficking defect and functional defect by mutations of the ATP-binding domains in the multidrug resistance protein 2 in patients with Dubin-Johnson syndrome Hepatology 36 2002 1236 1245
148. L. Beaudet, I.L. Urbatsch, and P. Gross Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphate activity Biochemistry 37 1998 9073 9082
149. 911 FEBS Lett. 577 2004 322 326
150. D.L. Mason, M.P. Mallampalli, G. Huyer, and S. Michaelis A region within the lumenal loop of Saccharomyces cerevisiae Ycf1p directs proteolytic processing and substrate specificity Eukaryot. Cell 2 2003 588 598
151. M.R. Picciotto, J.A. Cohn, G. Bertuzzi, P. Greengard, and A.C. Nairn Phosphorylation of the cystic fibrosis transmembrane conductance regulator J. Biol. Chem. 267 1992 12742 12752
152. D.C. Neville, C.R. Rozanas, E.M. Price, D.B. Gruis, A.S. Verkman, and R.R. Townsend Evidence for phosphorylation of serine 753 in CFTR using a novel metal-ion affinity resin and matrix-assisted laser desorption mass spectrometry Protein Sci. 6 1997 2436 2445
153. L. Csanady, D. Seto-Young, K.W. Chan, C. Cenciarelli, B.B. Angel, J. Qin, D.T. McLachlin, A.N. Krutchinsky, B.T. Chait, A.C. Nairn, and D.C. Gadsby Preferential phosphorylation of R-domain Ser768 dampens activation of CFTR channels by PKA J. Gen. Physiol. 125 2005 171 186
154. A.M. Dulhanty, X.B. Chang, and J.R. Riordan Mutation of potential phosphorylation sites in the recombinant R domain of the cystic fibrosis transmembrane conductance regulator has significant effects on domain conformation Biochem. Biophys. Res. Commun. 206 1995 207 214
155. D.C. Neville, C.R. Rozanas, B.M. Tulk, R.R. Townsend, and A.S. Verkman Expression and characterization of the NBD1-R domain region of CFTR: evidence for subunit-subunit interactions Biochemistry 37 1998 2401 2409
156. - channel by its R domain J. Biol. Chem. 276 2001 7689 7692
157. V. Chappe, D.A. Hinkson, T. Zhu, X.B. Chang, R.J. Riordan, and J.W. Hanrahan Phosphorylation of protein kinase C sites in NBD1 and the R domain control CFTR channel activation by PKA J. Physiol. 548 2003 39 52
158. V. Chappe, D.A. Hinkson, L.D. Howell, A. Evagelidis, J. Liao, X.B. Chang, R.J. Riordan, and J.W. Hanrahan Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator Proc. Natl. Acad. Sci. USA 101 2004 390 395
159. Y. Chen, B. Button, G.A. Altenberg, and L. Reuss Potentiation of effect of PKA stimulation of Xenopus CFTR by activation of PKC: role of NBD2 Am. J. Physiol. Cell Physiol. 287 2004 1426 1444
160. A. Vankeerberghen, L. Wei, M. Jaspers, J.J. Cassiman, B. Nilius, and H. Cuppens Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator Hum. Mol. Genet. 7 1998 1761 1769
161. E.A. Pasyk, X.K. Morin, P. Zeman, E. Garami, K. Galley, L.J. Huan, Y. Wang, and C.E. Bear A conserved region of the R domain of cystic fibrosis transmembrane conductance regulator is important in processing and function J. Biol. Chem. 273 1998 31759 31764
162. S. Gupta, J. Xie, J. Ma, and P.B. Davis Intermolecular interaction between R domain of cystic fibrosis transmembrane conductance regulator Am. J. Respir. Cell. Mol. Biol. 30 2004 242 248
163. J. Xie, L.M. Adams, J. Zhao, T.A. Gerken, P.B. Davis, and J. Ma A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification J. Biol. Chem. 277 2002 23019 23027
164. J.F. Cotten, and M.J. Welsh Covalent modification of the regulatory domain irreversibly stimulates cystic fibrosis transmembrane conductance regulator J. Biol. Chem. 272 1997 25617 25622
165. L. Wei, A. Vankeerberghen, H. Cuppens, G. Droogmans, J.J. Cassiman, and B. Nilus Phosphorylation site independent single R-domain mutations affect CFTR channel activity FEBS Lett. 439 1998 121 126
166. J. Fu, H.L. Ji, A.P. Naren, and K.L. Kirk A cluster of negative charges at the amino terminal tail of CFTR regulates ATP-dependent channel gating J. Physiol. 536 2001 459 470
167. J. Fu, and K.L. Kirk Cysteine substitutions reveal dual functions of the animo-terminal tail in cystic fibrosis transmembrane conductance regulator channel gating J. Biol. Chem. 276 2001 35660 35668
168. M. Cheung, and M.H. Akabas Locating the anion selectivity filter of the cystic transmembrane conductance regulator (CFTR). chloride channel J. Gen. Physiol. 109 1997 289 299
169. X. Xiong, A. Bragin, J.H. Widdicombe, J. Cohn, and W.R. Skach Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator J. Clin. Invest. 100 1997 1079 1088
170. D.N. Sheppard, S.M. Travis, H. Ishihara, and M.J. Welsh Contribution of proline residues in the membrane-spanning domains of CFTR to chloride channel function J. Biol. Chem. 271 1996 14995 15001
171. J.R. Riordan, J.M. Rommens, B.S. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.L. Chou, M.L. Drumm, M.C. Iannuzzi, F.S. Collins, and L.C. Tsui Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science 245 1989 1066 1073
172. F.S. Seibert, Y. Jia, C.J. Mathews, J.W. Hanrahan, J.R. Riordan, T.W. Loo, and D.M. Clarke Disease-associated mutations in the cytosolic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel Biochemistry 36 1997 11966 11974
173. A.W. Partridge, R.A. Melnyk, and C.M. Deber Polar residues in membrane domains of proteins: molecular basis for helix-helix association in a mutant CFTR transmembrane segment Biochemistry 41 2002 3647 3653
174. C.J. Ketchum, H. Yue, K.A. Alessi, S. Devidas, W.B. Guggino, and P.C. Maloney Intracellular cysteines of the cystic fibrosis transmembrane conductance regulator (CFTR) modulate channel gating Cell Physiol. Biochem. 12 2002 1 8
175. Z.R. Zhang, S.I. McDonough, and N.A. McCarty Interaction between permeation and gating in a putative pore domain mutant in the cystic fibrosis transmembrane conductance regulator Biophys. J. 79 2000 298 313
176. Z.R. Zhang, S. Zeltwanger, S.S. Smith, D.C. Dawson, and N.A. McCarty Voltage-sensitive gating induced by a mutation in the fifth transmembrane domain of CFTR Am. J. Physiol. Lung Cell. Mol. Physiol. 282 2002 L135 L145
177. N.A. McCarty Permeation through the CFTR chloride channel J. Exp. Biol. 203 2000 1947 1962
178. J. Gupta, A. Evagelidis, J.W. Hanrahan, and P. Linsdell Asymmetric structure of the cystic fibrosis transmembrane conductance regulator chloride channel pore suggested by mutagenesis of the twelfth transmembrane region Biochemistry 40 2001 6620 6627
179. J. Gupta, and P. Linsdell Point mutations in the pore region directly or indirectly affect glibenclamide block of the CFTR chloride channel Eur. J. Physiol. 443 2002 739 747
180. A. Vankeerberghen, L. Wei, M. Jaspers, J.J. Cassiman, B. Nilius, and H. Cuppens Characterization of mutations located in exon 18 of the CFTR gene FEBS Lett. 437 1998 1 4
181. J.F. Cotten, L.S. Ostedgaard, M.R. Carson, and M.J. Welsh Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator J. Biol. Chem. 271 1996 21279 21284
182. P. Fanen, R. Labarthe, F. Garnier, M. Benharouga, M. Goosens, and A. Edelman Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect J. Biol. Chem. 272 1997 30563 30566
183. M.I. Milewski, J.E. Mickle, J.K. Forrest, D.M. Stafford, B.D. Moyer, J. Cheng, W.B. Guggino, B.A. Stanton, and G.R. Cutting A PDZ-binding motif is essential but not sufficient to localize the C-terminus of CFTR to the apical membrane J. Cell Sci. 114 2000 719 726
184. W. Hu, M. Howard, and G.L. Lukacs Multiple endocytic signals in the C-terminal tail of the cystic fibrosis transmembrane conductance regulator Biochem. J. 354 2001 561 572
185. K. Peter, K. Varga, Z. Bebok, C.M. McNicholas-Bevensee, L. Schwiebert, E.J. Sorscher, E.M. Schwiebert, and J.F. Collawn Ablation of internalization signals in the carboxy-terminal tail of the cystic fibrosis transmembrane conductance regulator enhances cell surface expression J. Biol. Chem. 277 2002 49952 49957
186. J.A. Tabcharani, J.M. Rommens, Y.X. Hou, X.B. Chang, L.C. Tsui, J.R. Riordan, and J.W. Hanrahan Multi-ion pore behavior in the CFTR chloride channel Nature 366 1993 79 82
187. - channel expressed in mammalian cell lines J. Physiol. 512 1998 1 16
188. R. Guinamard, and M.H. Akabas Arg 352 is a major determinant of charge selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel Biochemistry 38 1999 5528 5537
189. P. Linsdell, A. Evagelidis, and J.W. Hanrahan Molecular determinants of anion selectivity in the cystic fibrosis transmembrane conductance regulator chloride channel pore Biophys. J. 78 2000 2973 2982
190. P. Linsdell Relationship between anion binding and anion permeability revealed by mutagenesis within the cystic fibrosis transmembrane conductance regulator chloride channel pore J. Physiol. 531 2001 51 66
191. - channel pore J. Physiol. 540 2002 39 47
192. S.S. Smith, X. Liu, Z.R. Zhang, F. Sun, T.E. Kriewall, N.A. McCarty, and D.C. Dawson CFTR: covalent and non-covalent modification suggests a role for fixed charges in anion conduction J. Gen. Physiol. 118 2001 407 431
193. X. Gong, and P. Linsdell Mutation-induced blocker permeability and multiion block of the CFTR chloride channel pore J. Gen. Physiol. 122 2003 673 687
194. I. Kogan, M. Ramjeesingh, L.J. Huan, Y. Wang, and C.E. Bear Perturbation of the pore of the cystic fibrosis transmembrane conductance regulator (CFTR) inhibits its ATPase activity J. Biol. Chem. 276 2001 11575 11581
195. J. Gupta, and P. Linsdell Extent of the selectivity filter conferred by the sixth transmembrane region in the CFTR chloride channel pore Mol. Membr. Biol. 20 2003 45 52
196. X. Gong, and P. Linsdell Molecular determinants and role of an anion binding site in the external mouth of the CFTR chloride channel pore J. Physiol. 549 2003 387 397
197. P. Linsdell, and J.W. Hanrahan Interaction of channel blockers with R347D-CFTR Ped. Pulmonol. Suppl. 14 1997 215
198. X. Liu, Z.R. Zhang, M.D. Fuller, J. Billingsley, N.A. McCarty, and D.C. Dawson CFTR: a cysteine at position 338 in TM6 senses a positive electrostatic potential in the pore Biophys. J. 87 2004 3826 3841
199. M.Y. Choi, A.W. Partridge, C. Daniels, K. Du, G.L. Lukacs, and C.M. Deber Destabilization of the transmembrane domain induces misfolding in a phenotypic mutant of cystic fibrosis transmembrane conductance regulator J. Biol. Chem. 280 2005 4968 4974
200. J.F. Cotten, and M.J. Welsh Cystic fibrosis-associated mutations at arginine 347 alter the pore architecture of CFTR. Evidence for disruption of a salt bridge J. Biol. Chem. 274 1999 5429 5435
201. J. Clain, J. Fritsch, J. Lehmann-Che, M. Bali, N. Arous, M. Goosens, A. Edelman, and P. Fanen Two mild cystic fibrosis-associated mutations result in severe cystic fibrosis when combined in cis and reveal a residue important for cystic fibrosis transmembrane conductance regulator processing and function J. Biol. Chem. 276 2001 9045 9049
202. K.F. Raab-Graham, L.J. Cirilo, A.A. Boettcher, C.M. Radeke, and C.A. Vandenberg Membrane topology of the amino-terminal region of the sulfonylurea receptor J. Biol. Chem. 274 1999 29122 29129
203. L.R. Conti, C.M. Radeke, and C.A. Vanderberg Membrane targeting of ATP-sensitive potassium channel J. Biol. Chem. 277 2002 25416 25422
204. S.L. Shyng, T. Ferrigni, J.B. Shepard, A. Nestorowizc, B. Glaser, M.A. Permutt, and C.G. Nichols Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy Diabetes 47 1998 1145 1151
205. C.J. Partridge, D.J. Beech, and A. Sivaprasadarao Identification and pharmalogical correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism J. Biol. Chem. 276 2001 35947 35952
206. ATP channels J. Biol. Chem. 277 2002 17139 17146
207. + channels by G-protein βγ-subunits EMBO J. 19 2000 4915 4925
208. +channels Prog. Biophys. Mol. Biol. 81 2003 133 176
209. ATP channel Diabetes 48 1999 1341 1347
210. A. Hambrock, C. Loffler-Walz, U. Russ, U. Lange, and U. Quast Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes Mol. Pharmacol. 60 2001 190 199
211. A. Hambrock, C. Loffler-Walz, and U. Quast Glibenclamide binding to sulfonylurea receptor subtypes: dependence on adenine nucleotides Br. J. Pharmacol. 136 2002 995 1004
212. D. Stephan, E. Stauss, U. Lange, H. Felsch, C. Loffer-Walz, A. Hambrock, U. Russ, and U. Quast The mutation Y1206S increases the affinity of the sulfonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2 Br. J. Pharmacol. 144 2005 1078 1088
213. ATP channel FEBS Lett. 499 2001 154 160
214. + channels Diabetes 53 2004 S104 S112
215. F. Yan, C.W. Lin, E. Weisiger, E.A. Cartier, G. Taschenberger, and S.L. Shyng Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor J. Biol. Chem. 279 2004 11096 11105
216. + channel modulators Diabetes 53 2004 S128 S134
217. ATP channels openers Mol. Pharmacol. 67 2005 1026 1033
218. D.W. Zhang, S.P.C. Cole, and R.G. Deeley Determinants for substrate specifity of multidrug resistance protein 1 J. Biol. Chem. 277 2002 20934 20941
219. 4 Biochemistry 41 2002 14132 14140
220. L. Ito, C.J. Oleschuk, C. Westlake, M.Z. Vasa, R.G. Deeley, and S.P.C. Cole Mutation of Trp 1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2) alters substrate specificity and results in loss of methotrexate transport activity J. Biol. Chem. 276 2001 38108 38114
221. D.W. Zhang, H.M. Gu, M. Vasa, M. Muredda, S.P.C Cole, and R.G. Deeley Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3 Biochemistry 42 2003 9989 10000
222. ATP channels J. Biol. Chem. 274 1999 20628 20632
223. K.I. Ito, K.E. Weigl, R.G. Deeley, and S.P.C. Cole Mutation of proline residues in the NH2-terminal region of the multidrug resistance protein MRP1 (ABCC1): effects on protein expression, membrane localization and transport function Biochim. Biophys. Acta 1615 2003 103 114
224. 2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1) Biochemistry 13 2003 5214 5224
225. 4 J. Biol. Chem. 273 1998 10733 10740
226. C.J. Westlake, S.P.C. Cole, and R.G. Deeley Role of the NH2-terminal membrane spanning domain of MRP1/ABCC1 in protein processing and trafficking Mol. Biol. Cell 16 2005 2483 2492
227. 35S]glutathione J. Biol. Chem. 277 2002 35225 35231
228. A. Haimeur, G. Conseil, R.G. Deeley, and S.P.C. Cole Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1(ABCC1) Mol. Pharmacol. 65 2004 1375 1385
229. K. Koike, G. Conseil, E.M. Leslie, R.G. Deeley, and S.P.C. Cole Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity and nucleotide interactions J. Biol. Chem. 279 2004 12325 12336
230. E.M. Leslie, K. Ito, P. Upadhyaya, S.S. Hecht, R.G. Deeley, and S.P.C. Cole Transport of the β-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1/ABCC1): requirement for glutathione or a non-sulfur-containing analog J. Biol. Chem. 276 2001 27846 27854
231. S. Conrad, H.M. Kauffmann, K.I. Ito, E.M. Leslie, R.G. Deeley, D. Schrenk, and S.P.C. Cole A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance Pharmacogenetics 12 2002 321 330
232. 594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1) J. Biol. Chem. 279 2004 463 468
233. D. Situ, A. Haimeur, G. Conseil, K.E. Sparks, D. Zhang, R.G. Deeley, and S.P.C. Cole Mutational analysis of ionizable residues proximal to the cytoplasmic interface of membrane spanning domain 3 of the multidrug resistance protein, MRP1 (ABCC1): glutamate 1204 is important for both the expression and catalytic activity of the transporter J. Biol. Chem. 279 2004 38871 38880
234. D.W. Zhang, H.M. Gu, D. Situ, A. Haimeur, S.P.C. Cole, and R.G. Deeley Functional importance of polar and charged amino acid residues in transmembrane helix 14 of multidrug resistance protein 1 (MRP1/ABCC1): identification of an aspartate residue critical for conversion from a high to a low affinity substrate binding state J. Biol. Chem. 278 2003 46052 46063
235. D.W. Zhang, S.P.C. Cole, and R.G. Deeley Identification of an amino acid residue in multidrug resistance protein (MRP) 1 critical for conferring resistance to anthracyclines J. Biol. Chem. 276 2001 13231 13239
236. S. Ito, I. Ieiri, M. Tanabe, A. Suzuki, S. Higuchi, and K. Otsubo Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects Pharmacogenetics 11 2001 175 184
237. C.J. Westlake, L. Payen, M. Gao, S.P.C. Cole, and R.G. Deeley Identification and characterization of functionally important elements of the multidrug resistance protein 1 COOH-terminal region J. Biol. Chem. 279 2004 53571 53583
238. S. Ryu, T. Kawabe, S. Nada, and A. Yamaguchi Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2 J. Biol. Chem. 275 2000 39617 39624
239. S.B. Fernandez, Z. Hollo, A. Kern, E. Bakos, P.A. Fischer, P. Borst, and R. Evers Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells J. Biol. Chem. 277 2002 31048 31055
240. V. Materna, and H. Lage Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient J. Hum. Genet. 48 2003 484 486
241. V. Keitel, A.T. Nies, M. Brom, J. Hummel-Eisenbeiss, H. Spring, and D. Keppler A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2) Am. J. Physiol. Gastroinvest. Liver Physiol. 284 2003 G165 G174
242. N. Zelcer, M.T. Huisman, G. Reid, P. Wielinga, P. Breedveld, A. Kuil, P. Knipscheer, J.H.M. Schellens, A.H. Schinkel, and P. Borst Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2) J. Biol. Chem. 278 2003 23538 23544
243. T.W. Loo, and D.M. Clarke Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein J. Biol. Chem. 268 1993 3143 3149
244. S. Dey, P. Haftemeyer, I. Pastan, and M.M. Gottesman A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol Biochemistry 38 1999 6630 6639
245. T.W. Loo, and D.M. Clarke Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein J. Biol. Chem. 269 1994 7243 7248
246. H. Omote, R.A. Figler, M.K. Polar, and M.K. Al-Shawi Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation Biochemistry 43 2004 3917 3928
247. K. Ueda, Y. Taguchi, and M. Morishima How does P-glycoprotein recognize its substrates? Semin. Cancer Biol. 8 1997 151 159
248. T.W. Loo, and D.M. Clarke Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein Biochem. Cell Biol. 77 1999 11 23
249. T.W. Loo, and D.M. Clarke Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein J. Biol. Chem. 277 2002 44332 44338
250. P. Hafkemeyer, S. Dey, S.V. Ambudkar, C.A. Hrycyna, I. Pastan, and M.M. Gottesman Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein Biochemistry 37 1998 16400 16409
251. T.W. Loo, and D.M. Clarke Defining the drug-binding site of the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil J. Biol. Chem. 276 2001 14972 14979
252. A. Rothnie, J. Storm, R. McMahon, A. Taylor, I.D. Kerr, and R. Callaghan The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment FEBS Lett. 579 2005 3984 3990
253. J. Song, and P.W. Melera Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis Cancer Chemother. Pharmacol. 48 2001 339 346
254. 125I] iodoarylazidoprazosin labeling Mol. Pharmacol. 60 2001 254 261
255. T.W. Loo, M.C. Bartlett, and D.M. Clarke ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein Biochemistry 44 2005 10250 10258
256. T.W. Loo, M.C. Bartlett, and D.M. Clarke Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains J. Biol. Chem. 279 2004 38395 38401
257. M. Demeule, A. Laplante, G.F. Murphy, R.M. Wenger, and R. Beliveau Identification of the cyclosporin-binding site in P-glycoprotein Biochemistry 37 1998 18110 18118
258. J.F. Ma, G. Grant, and P.W. Melera Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporine A reversal Mol. Pharmacol. 51 1997 922 930
259. T.W. Loo, M.C. Bartlett, and D.M. Clarke The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not for activity J. Biol. Chem. 280 2005 2522 2528
260. A.L. Davidson, and J. Chen ATP-binding cassette transporters in bacteria Annu. Rev. Biochem. 73 2004 241 268
261. K.P. Locher, A.T. Lee, and D.C. Rees The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism Science 296 2002 1091 1098
262. R.B. Bass, K.P. Locher, E. Borths, Y. Poon, P. Strop, A. Lee, and D.C. Rees The structures of BtuCD and MscS and their implications for transporter and channel function FEBS Lett. 555 2003 111 115
263. K.P. Locher, and E. Borths ABC transporter architecture and mechanism: implications from the crystal structures of BtuCD and BtuF FEBS Lett. 564 2004 264 268
264. E.L. Borths, B. Poolman, R.N. Hvorup, K.P. Locher, and D.C. Rees In vitro functional characterization of BtuCD-F, the Escherichia coli ABC transporter for vitamin B(12) uptake Biochemistry 44 2005 16301 16309
265. G. Chang, and C.B. Roth Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters Science 293 2001 1793 1800
266. M.F. Rosenberg, Q. Mao, A. Holzenburg, R.C. Ford, R.G. Deeley, and S.P. Cole The structure of the multidrug resistance protein 1 (MRP1/ABCC1). Crystallization and single particle analysis J. Biol. Chem. 276 2001 16076 16082
267. M.F. Rosenberg, A.B. Kamis, R. Callaghan, C.F. Higgins, and R.C. Ford Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding J. Biol. Chem. 278 2003 8294 8299
268. N.H. Awayn, M.F. Rosenberg, A.B. Kamis, L.A. Aleksandrov, J.R. Riordan, and R.C. Ford Crystallographic and single-particle analyses of native- and nucleotide-bound forms of the cystic fibrosis transmembrane conductance regulator (CFTR) protein Biochem. Soc. Trans. 33 2005 996 999
269. M.V. Mikhailov, J.D. Campbell, H. de Wet, K. Shimomura, B. Zadek, R.F. Collins, M.S. Sansom, R.C. Ford, and F.M. Ashcroft 3-D structural and functional characterization of the purified K(ATP) channel complex Kir6.2-SUR1 EMBO J. 24 2005 4166 4175
270. M.F. Rosenberg, R. Callaghan, S. Modok, C.F. Higgins, and R.C. Ford Three dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state J. Biol. Chem. 280 2005 2857 2862
271. C.F. Higgins, and K.J. Linton The ATP switch model for ABC transporters Nat. Struct. Mol. Biol. 11 2004 918 926